CD82 and triple-negative breast carcinoma: This study investigates the hypothesis that palmitoylation-deficient CD82 mutants sensitize triple-negative breast cancer cells to chemotherapy by disrupting membrane microdomains and amplifying intrinsic apoptosis, thereby offering a novel combinatorial therapeutic strategy.